FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
American journal of respiratory and critical care medicine2022; 207(1); 11-13; doi: 10.1164/rccm.202208-1639ED

Criteria for Progressive Pulmonary Fibrosis: Getting the Horse Ready for the Cart.

Abstract: No abstract available
Get Full Text
Publication Date: 2022-09-07 PubMed ID: 36066856PubMed Central: PMC9952875DOI: 10.1164/rccm.202208-1639EDGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Editorial
  • Comment

Cite This Article

APA
Cottin V. (2022). Criteria for Progressive Pulmonary Fibrosis: Getting the Horse Ready for the Cart. Am J Respir Crit Care Med, 207(1), 11-13. https://doi.org/10.1164/rccm.202208-1639ED

Publication

American journal of respiratory and critical care medicine
ISSN: 1535-4970
NlmUniqueID: 9421642
Country: United States
Language: English
Volume: 207
Issue: 1
Pages: 11-13

Researcher Affiliations

Cottin, Vincent
  • National Reference Centre for Rare Pulmonary Diseases Louis Pradel Hospital, Hospices Civils de Lyon Lyon, France.
  • UMR 754, Institut national de recherche agronomique et environnement Claude Bernard University Lyon 1 Lyon, France.

MeSH Terms

  • Horses
  • Animals
  • Pulmonary Fibrosis

References

This article includes 23 references
  1. Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, Kreuter M, Lynch DA, Maher TM, Martinez FJ, Molina-Molina M, Myers JL, Nicholson AG, Ryerson CJ, Strek ME, Troy LK, Wijsenbeek M, Mammen MJ, Hossain T, Bissell BD, Herman DD, Hon SM, Kheir F, Khor YH, Macrea M, Antoniou KM, Bouros D, Buendia-Roldan I, Caro F, Crestani B, Ho L, Morisset J, Olson AL, Podolanczuk A, Poletti V, Selman M, Ewing T, Jones S, Knight SL, Ghazipura M, Wilson KC. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.. Am J Respir Crit Care Med 2022 May 1;205(9):e18-e47.
    pmc: PMC9851481pubmed: 35486072doi: 10.1164/rccm.202202-0399STgoogle scholar: lookup
  2. Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ. What's in a name? That which we call IPF, by any other name would act the same.. Eur Respir J 2018 May;51(5).
    pubmed: 29773608doi: 10.1183/13993003.00692-2018google scholar: lookup
  3. Brown KK, Martinez FJ, Walsh SLF, Thannickal VJ, Prasse A, Schlenker-Herceg R, Goeldner RG, Clerisme-Beaty E, Tetzlaff K, Cottin V, Wells AU. The natural history of progressive fibrosing interstitial lung diseases.. Eur Respir J 2020 Jun;55(6).
    pmc: PMC7315005pubmed: 32217654doi: 10.1183/13993003.00085-2020google scholar: lookup
  4. Wijsenbeek M, Cottin V. Spectrum of Fibrotic Lung Diseases.. N Engl J Med 2020 Sep 3;383(10):958-968.
    pubmed: 32877584doi: 10.1056/NEJMra2005230google scholar: lookup
  5. Cottin V, Teague R, Nicholson L, Langham S, Baldwin M. The Burden of Progressive-Fibrosing Interstitial Lung Diseases.. Front Med (Lausanne) 2022;9:799912.
    pmc: PMC8843847pubmed: 35178411doi: 10.3389/fmed.2022.799912google scholar: lookup
  6. Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, Veeraraghavan S, Hansell DM, Wells AU. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends.. Am J Respir Crit Care Med 2003 Sep 1;168(5):531-7.
    pubmed: 12791580doi: 10.1164/rccm.200210-1245OCgoogle scholar: lookup
  7. Jegal Y, Kim DS, Shim TS, Lim CM, Do Lee S, Koh Y, Kim WS, Kim WD, Lee JS, Travis WD, Kitaichi M, Colby TV. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia.. Am J Respir Crit Care Med 2005 Mar 15;171(6):639-44.
    pubmed: 15640368doi: 10.1164/rccm.200403-331OCgoogle scholar: lookup
  8. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.. Am J Respir Crit Care Med 2013 Sep 15;188(6):733-48.
    pmc: PMC5803655pubmed: 24032382doi: 10.1164/rccm.201308-1483STgoogle scholar: lookup
  9. Solomon JJ, Chung JH, Cosgrove GP, Demoruelle MK, Fernandez-Perez ER, Fischer A, Frankel SK, Hobbs SB, Huie TJ, Ketzer J, Mannina A, Olson AL, Russell G, Tsuchiya Y, Yunt ZX, Zelarney PT, Brown KK, Swigris JJ. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease.. Eur Respir J 2016 Feb;47(2):588-96.
    pubmed: 26585429doi: 10.1183/13993003.00357-2015google scholar: lookup
  10. Goh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, Maher TM, Nicholson AG, Wells AU. Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.. Arthritis Rheumatol 2017 Aug;69(8):1670-1678.
    pubmed: 28426895doi: 10.1002/art.40130google scholar: lookup
  11. Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.. N Engl J Med 2019 Oct 31;381(18):1718-1727.
    pubmed: 31566307doi: 10.1056/NEJMoa1908681google scholar: lookup
  12. Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.. Lancet Respir Med 2020 May;8(5):453-460.
    pubmed: 32145830doi: 10.1016/S2213-2600(20)30036-9google scholar: lookup
  13. Nasser M, Larrieu S, Si-Mohamed S, Ahmad K, Boussel L, Brevet M, Chalabreysse L, Fabre C, Marque S, Revel D, Thivolet-Bejui F, Traclet J, Zeghmar S, Maucort-Boulch D, Cottin V. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study).. Eur Respir J 2021 Feb;57(2).
    pmc: PMC8411897pubmed: 32943410doi: 10.1183/13993003.02718-2020google scholar: lookup
  14. Takei R, Brown KK, Yamano Y, Kataoka K, Yokoyama T, Matsuda T, Kimura T, Suzuki A, Furukawa T, Fukuoka J, Johkoh T, Goto Y, Kondoh Y. Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype.. Respirology 2022 May;27(5):333-340.
    pubmed: 35293077doi: 10.1111/resp.14245google scholar: lookup
  15. Hambly N, Farooqi MM, Dvorkin-Gheva A, Donohoe K, Garlick K, Scallan C, Chong SG, MacIsaac S, Assayag D, Johannson KA, Fell CD, Marcoux V, Manganas H, Morisset J, Comes A, Fisher JH, Shapera S, Gershon AS, To T, Wong AW, Sadatsafavi M, Wilcox PG, Halayko AJ, Khalil N, Cox G, Richeldi L, Ryerson CJ, Kolb M. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry.. Eur Respir J 2022 Oct;60(4).
    doi: 10.1183/13993003.02571-2021pubmed: 35273032google scholar: lookup
  16. Oldham JM, Lee CT, Wu Z, Bowman WS, Pugashetti JV, Dao N, Tonkin J, Seede H, Echt G, Adegunsoye A, Chua F, Maher TM, Garcia CK, Strek ME, Newton CA, Molyneaux PL. Lung function trajectory in progressive fibrosing interstitial lung disease.. Eur Respir J 2022 Jun;59(6).
    pmc: PMC10039317pubmed: 34737223doi: 10.1183/13993003.01396-2021google scholar: lookup
  17. George PM, Spagnolo P, Kreuter M, Altinisik G, Bonifazi M, Martinez FJ, Molyneaux PL, Renzoni EA, Richeldi L, Tomassetti S, Valenzuela C, Vancheri C, Varone F, Cottin V, Costabel U. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities.. Lancet Respir Med 2020 Sep;8(9):925-934.
    pubmed: 32890499doi: 10.1016/S2213-2600(20)30355-6google scholar: lookup
  18. Johannson KA, Kolb M, Fisher JH, Walsh SLF. Progressive Pulmonary Fibrosis: Putting the Cart Before the Horse.. Am J Respir Crit Care Med 2022 Nov 15;206(10):1294-1295.
    pmc: PMC9746832pubmed: 35868031doi: 10.1164/rccm.202206-1166LEgoogle scholar: lookup
  19. Pugashetti JV, Adegunsoye A, Wu Z, Lee CT, Srikrishnan A, Ghodrati S, Vo V, Renzoni EA, Wells AU, Garcia CK, Chua F, Newton CA, Molyneaux PL, Oldham JM. Validation of Proposed Criteria for Progressive Pulmonary Fibrosis.. Am J Respir Crit Care Med 2023 Jan 1;207(1):69-76.
    pmc: PMC9952866pubmed: 35943866doi: 10.1164/rccm.202201-0124OCgoogle scholar: lookup
  20. Khor YH, Farooqi M, Hambly N, Kolb M, Ryerson CJ. Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions.. Am J Respir Crit Care Med 2023 Jan 1;207(1):102-105.
    pmc: PMC9952865pubmed: 35943331doi: 10.1164/rccm.202205-0910LEgoogle scholar: lookup
  21. Maher TM, Brown KK, Kreuter M, Devaraj A, Walsh SLF, Lancaster LH, Belloli EA, Padilla M, Behr J, Goeldner RG, Tetzlaff K, Schlenker-Herceg R, Flaherty KR. Effects of nintedanib by inclusion criteria for progression of interstitial lung disease.. Eur Respir J 2022 Feb;59(2).
    pmc: PMC8812469pubmed: 34210788doi: 10.1183/13993003.04587-2020google scholar: lookup
  22. Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.. Lancet Respir Med 2020 Feb;8(2):147-157.
    pubmed: 31578169doi: 10.1016/S2213-2600(19)30341-8google scholar: lookup
  23. Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, Bonnet R, Grohe C, Held M, Wilkens H, Hammerl P, Koschel D, Blaas S, Wirtz H, Ficker JH, Neumeister W, Schönfeld N, Claussen M, Kneidinger N, Frankenberger M, Hummler S, Kahn N, Tello S, Freise J, Welte T, Neuser P, Günther A. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.. Lancet Respir Med 2021 May;9(5):476-486.
    pubmed: 33798455doi: 10.1016/S2213-2600(20)30554-3google scholar: lookup

Citations

This article has been cited 5 times.
  1. Montero IE, Hernandez-Gonzalez F, Sellares J. Epidemiology and Prognosis of Progressive Pulmonary Fibrosis: A Literature Review. Pulm Ther 2025 Sep;11(3):347-363.
    doi: 10.1007/s41030-025-00302-5pubmed: 40522429google scholar: lookup
  2. Nowak S, Creuzberg D, Theis M, Pizarro C, Isaak A, Pieper CC, Luetkens JA, Skowasch D, Sprinkart AM, Kütting D. Comparing multi-texture fibrosis analysis versus binary opacity-based abnormality detection for quantitative assessment of idiopathic pulmonary fibrosis. Sci Rep 2025 Jan 9;15(1):1479.
    doi: 10.1038/s41598-025-85135-7pubmed: 39789082google scholar: lookup
  3. Pande A, Haouzi P. Inbuilt Errors: A Call for Standardized Definitions. Am J Respir Crit Care Med 2025 Apr;211(4):663-664.
    doi: 10.1164/rccm.202411-2183LEpubmed: 39680937google scholar: lookup
  4. Hofman DE, Magrì T, Moor CC, Richeldi L, Wijsenbeek MS, Waseda Y. Patient-centered care in pulmonary fibrosis: access, anticipate, and act. Respir Res 2024 Nov 1;25(1):395.
    doi: 10.1186/s12931-024-02997-7pubmed: 39487454google scholar: lookup
  5. Calaras D, David A, Vasarmidi E, Antoniou K, Corlateanu A. Hypersensitivity Pneumonitis: Challenges of a Complex Disease. Can Respir J 2024;2024:4919951.
    doi: 10.1155/2024/4919951pubmed: 38283656google scholar: lookup
Subscribe to our newsletter
Join 99,850 horse owners like you who receive our email updates on horse health and nutrition.